ClinicalTrials.gg
Drug

ZSP1273 clinical trials

Also written ZSP1273.

studies test it
14
open now
0
in phase 3
3
first study started
2018

How each study uses ZSP1273 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

ZSP1273 granules
2
ZSP1273 600 mg
2
ZSP1273 200 mg
2

Development codes

ZSP1273
9

Studies by the year they started

14 studies that test it; most in 2023 (6)

Studies that test ZSP1273, by start year
YearStudies
20181
20191
20202
20236
20242
20252

By phase

A phase 1/2 study counts in both.

Phase 1
9
Phase 2
2
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 14 · Other 0

Guangdong Raynovent Biotech Co., Ltd (13) · Guangdong Zhongsheng Pharmaceutical Co., Ltd. (1)

Often tested with

Tested in the same studies.

Oseltamivir (1)

Studies

Open first, then newest update. How each study uses ZSP1273 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 14